GlaxoSmithKline Pharmaceutical Sdn Bhd (GSK) today announced that the Arexvy vaccine (MAL24086007ARZ) has been approved in Malaysia for respiratory syncytial virus (RSV). RSV is a common respiratory ...
7hon MSN
Sanofi has received two separate bids from private equity firms for its consumer health unit, which could be valued at 15 ...
Novo Nordisk’s weight loss drug Wegovy could face Medicare price negotiations next. Meanwhile, Particle Health files an ...
GSK PLC GSK shares inched up 0.20% to £15.31 Tuesday, on what proved to be an all-around favorable trading session for the ...
If approved, AZN's Fasenra will be the second biologic approved in the European Union to treat eosinophilic granulomatosis ...
UCB and Biogen revealed that their Phase 3 study testing dapirolizumab pegol in people with systemic lupus erythematosus met ...
Arexvy has been approved in Malaysia for RSV (respiratory syncytial virus), for older adults aged 60 and above. The vaccine ...
Biogen and Belgian partner UCB said on Tuesday their experimental lupus treatment met the main goal of a late-stage trial in ...
A groundbreaking study will investigate Parkinson’s disease in unprecedented detail, with the aim of discovering a cure for ...
Cancer Vaccines Market revenue is expected to hold around USD 24.22 billion by 2033 from USD 9 million in 2023 with a ...
The pre-competitive scientific research consortium of top pharmaceutical companies remains a critical force in advancing qualified PBPK modeling and simulation to further drug development and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback